<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02681016</url>
  </required_header>
  <id_info>
    <org_study_id>PAT1.0</org_study_id>
    <nct_id>NCT02681016</nct_id>
  </id_info>
  <brief_title>Sirolimus-eluting Stent CALYPSO vs Everolimus-eluting Stent XIENCE</brief_title>
  <acronym>PATRIOT</acronym>
  <official_title>Prospective rAndomized, Single-blind, multicenTral Control Clinical Trial of Sirolimus-eluting coRonary Stent &quot;Calypso&quot; (Angioline) vs Everolimus-elutIng cOronary stenT &quot;Xience Prime&quot; (Abbott Vascular)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Meshalkin Research Institute of Pathology of Circulation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Meshalkin Research Institute of Pathology of Circulation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to evaluate the efficacy and safety of sirolimus-eluting coronary
      stent &quot;Calypso&quot; (Angioline, Russia) in comparison with everolimus-eluting coronary stent
      &quot;Xience&quot; (Abbott Vascular, USA)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2015</start_date>
  <completion_date type="Actual">July 2017</completion_date>
  <primary_completion_date type="Actual">July 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Target lesion failure</measure>
    <time_frame>during 1 year after procedure</time_frame>
    <description>Primary outcome is defined as a composite endpoint of cardiac death, target vessel myocardial infarction and clinically indicated target lesion revascularization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>1 year major adverse cardiac and cerebrovascular events (MACCE)</measure>
    <time_frame>during 1 year after procedure</time_frame>
    <description>1 year major adverse cardiac and cerebrovascular events (MACCE) including: All-cause mortality, Myocardial infarction, Stroke, Stent thrombosis, Clinically indicated Target lesion revascularization, Any target lesion revascularization, Any target vessel revascularization.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Angiographic endpoint</measure>
    <time_frame>1 year after procedure</time_frame>
    <description>Estimation of target lesion late lumen loss in randomly selected 20% of the subjects.</description>
  </other_outcome>
  <other_outcome>
    <measure>Device success</measure>
    <time_frame>procedure</time_frame>
    <description>Device success is defined as achievement of a final residual diameter stenosis 20% during the initial procedure.</description>
  </other_outcome>
  <other_outcome>
    <measure>Lesion success</measure>
    <time_frame>procedure</time_frame>
    <description>Lesion success, defined as achievement of a final residual diameter stenosis 20% with use of any PCI approach.</description>
  </other_outcome>
  <other_outcome>
    <measure>In-hospital procedure success</measure>
    <time_frame>Within 5-day hospitalization</time_frame>
    <description>Procedure success is defined as achievement of a final residual diameter stenosis 20% together with the absence of any in-hospital major adverse cardiac event. The 5-day hospitalization time frame was evaluated according to the standards of health care in patients was coronary angioplasty in Russia.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">610</enrollment>
  <condition>Ischemic Heart Disease</condition>
  <condition>Coronary Atherosclerosis</condition>
  <condition>Coronary Artery Disease</condition>
  <condition>Coronary Artery Stenosis</condition>
  <arm_group>
    <arm_group_label>Sirolimus-eluting stent &quot;Calypso&quot;</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Commercially approved coronary stent system &quot;Calypso&quot; (Angioline, Russia) Coating - Sirolimus(rapamicine) Stent diameters: 2.0, 2.25, 2.5, 2.75, 3.0, 3.5, 4.0, 4.5 mm. Stent lengths: 8, 13, 15, 18, 23, 28, 33, 38 mm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Everolimus-eluting stent &quot;Xience Prime&quot;</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Commercially approved XIENCE PRIME, (Abbott Vascular, USA) Coating - Everolimus with concentration Stent diameters: 2.25, 2.5, 2.75, 3.0, 3.5, 4.0 mm. Stent lengths: 8, 12, 15, 18, 23, 28, 33, 38 mm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DES &quot;Calypso&quot;</intervention_name>
    <description>A standard endovascular procedure is carried out under local anesthesia and under fluoroscopic control. Stenosis of coronary artery is passed by the hydrophilic coronary wire. Then balloon angioplasty of target lesion (if required) is provided. After the angiographic control coronary stent is implanted. After coronary wire removing control angiographic study is provided. Medical therapy includes aspirin(acid acetylsalicylic) 125 - 300 mg/d and plavix(clopidogrel) in dose 300-600 mg prescription before the procedure and heparin (heparin sodium) injection during the procedure(5000 U iv). After the procedure aspirin(acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and plavix(clopidogrel) in dose 75/d should be prescribed within 12 months.</description>
    <arm_group_label>Sirolimus-eluting stent &quot;Calypso&quot;</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DES &quot;Xience Prime&quot;</intervention_name>
    <description>A standard endovascular procedure is carried out under local anesthesia and under fluoroscopic control. Stenosis of coronary artery is passed by the hydrophilic coronary wire. Then balloon angioplasty of target lesion (if required) is provided. After the angiographic control coronary stent is implanted. After coronary wire removing control angiographic study is provided. Medical therapy includes aspirin(acid acetylsalicylic) 125 - 300 mg/d and plavix(clopidogrel) in dose 300-600 mg prescription before the procedure and heparin (heparin sodium) injection during the procedure(5000 U iv). After the procedure aspirin(acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and plavix(clopidogrel) in dose 75/d should be prescribed within 12 months.</description>
    <arm_group_label>Everolimus-eluting stent &quot;Xience Prime&quot;</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Coronary angioplasty</intervention_name>
    <arm_group_label>Sirolimus-eluting stent &quot;Calypso&quot;</arm_group_label>
    <arm_group_label>Everolimus-eluting stent &quot;Xience Prime&quot;</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients considered for coronary angioplasty with stenting due to Ischemic heart
             disease (Stable angina, Unstable angina, non-ST Myocardial Infarction).

          -  Target vessel lesion in coronary artery with diameter measurements &gt;2.5 mm &amp; &lt; 4.5 mm.

          -  Signed, documented informed consent prior to admission to the study

        Exclusion Criteria:

          -  Age &lt;18 years or &gt;75 years

          -  Renal insufficiency (GFR/MDRD &lt;30 ml/min)

          -  Subject has a platelet count &lt; 100,000 cells/mm3 or &gt; 700,000 cells/mm3.

          -  Known non-adherence to DAPT

          -  LVEF &lt;30%

          -  Known oncology

          -  Severe cardiac valvular pathology, requiring operative treatment within 1 year

          -  Anemia (HB&lt;100 g/l)

          -  Continuing bleeding

          -  Acute coronary syndrome (ST-elevation Myocardial infarction)

          -  Anamnesis of previous coronary angioplasty/stenting or CABG

          -  NYHA class (dyspnoea) IV or hospitalization during last year due to Chronic cardiac
             failure as a primary diagnosis.

          -  Pregnancy

          -  Coronary pathology requiring CABG or staged scheduled coronary angioplasty/stenting
             except cases of unscheduled staged coronary angioplasty/stenting within 4 weeks after
             primary procedure.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>State Research Institute of CIrculation Pathology</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630055</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 19, 2016</study_first_submitted>
  <study_first_submitted_qc>February 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2016</study_first_posted>
  <last_update_submitted>December 14, 2017</last_update_submitted>
  <last_update_submitted_qc>December 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Calypso</keyword>
  <keyword>Xience</keyword>
  <keyword>Coronary stenosis</keyword>
  <keyword>Drug-eluting stent</keyword>
  <keyword>Coronary angioplasty with stenting</keyword>
  <keyword>Ischemic Heart Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Coronary Stenosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

